Scientific Areas of Interest

Loxo Oncology at Lilly is actively seeking partnerships with world-class industry and academic collaborators in order to optimize and accelerate the development of new cancer medicines. We are focused on opportunities across discovery and development stage assets with the potential to:

• Demonstrate unequivocal activity early in the drug development process

• Deliver outsized and differentiated effects for patients

We are agnostic to the biologic basis of programs, so long as we have high conviction in the science and believe they will matter for patients. Find more information about Loxo Oncology at Lilly here.

Lilly has been a global leader in diabetes care for over 140 years and remains strongly committed to innovation in diabetes research.

Glycemic Control and Disease Modification

• Glucose-Sensing Insulins or Other Insulins with Reduced Hypoglycemia

• Next Generation Immunomodulation

• Islet Cell and Immunotherapies for Type 1 Diabetes

• Type 2 Diabetes Regression and Durability of Response (e.g. Modifiers of beta-cell health)

Diabetes Complications

• Obesity

 

• Heart Failure

 

• Atherosclerotic Cardiovascular Disease

 

• Chronic Kidney Disease

 

• NASH

 

• Diabetic Neuropathy (Disease Modifying)

Technologies

• Oral Peptide Delivery

 

• Gene Editing and Delivery

Out of Scope

• Insulin Secretagogues with No Added Metabolic Benefits

• Oral/Inhaled Insulins

• Gestational Diabetes

• Wound Healing

• Gastroparesis

• Anticoagulants

• Acute Myocardial Infarction/Ischemia-Reperfusion Therapies

• Acute/Ischemic stroke

• Arrhythmia

• Peripheral Arterial Disease

• Retinopathy

• Neuropathy (unless disease modifying)

Lilly is committed to finding medicines for the treatment of Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

Focus Indications

• Alzheimer’s Disease

 

• Parkinson’s Disease

  

• Amyotrophic Lateral Sclerosis (ALS)

  

• Other related proteinopathies (e.g. HD, PSP, MSA, FTD)

 

• Related Monogenic Neurodegenerative Conditions (e.g., lysosomal storage disorders, leukodystrophies)

• Other Neurological diseases

Fields of Interest

• Protein misfolding - Inhibiting intra-neuronal accumulation, aggregation and spreading of misfolded pathological protein species

• Innate Immune Response and Neuroinflammation - Enhancing the glial neuroprotective response in neurodegenerative disease. Reducing inflammation in the brain by modulation of involved pathways, for example microglia, astrocytes, complement cascade

• Proteostasis - Maintaining protein homeostasis through protein degradation, protein stabilization, protein-protein interaction modulation, autophagy modulation

• Mechanisms of Neurodegeneration – Blocking pathways that underlie neuro-, axonal- and synaptic degeneration

• Symptomatic Treatments - Psychosis, cognitive impairment, agitation, mood, movement and sleep

Technologies

• Blood-brain-barrier delivery

• Protein knockdown (e.g. siRNA, protein degradation)

• Exon Splicing Modulation (small and large molecule modalities, gene up-regulation or down regulation)

• Gene therapy and editing

• Blood-based biomarkers for Alzheimer’s or Parkinson’s disease

 

Out of Scope

• CNS injuries (stroke, TBI, SCI)

Lilly has the largest pipeline of novel medicines for the treatment of chronic pain.

Focus Indications

• Chronic neuropathic pain (e.g. diabetic peripheral neuropathic pain, neuropathic back pain, post-traumatic neuropathic pain)

• Musculoskeletal pain (e.g. osteoarthritis, chronic low back pain, degenerative disc disease, fibromyalgia)

• Visceral pain (e.g. irritable bowel syndrome, functional dyspepsia, residual pain in inflammatory bowel disease)

• Migraine and other forms of disabling headache

• Peripheral neuropathies

• Other neurological disorders characterized by neuronal hyperexcitability, particularly when genetically defined (e.g. seizures)

Fields of Interest

• Symptomatic relief of pain and improvement of function

• Prevention or repair of peripheral nerve damage and neuropathies (e.g. diabetic neuropathy, chemotherapy-induced neuropathy, inherited neuropathies)

• Therapies that prevent damage or repair joints in musculoskeletal disease

Technologies

• Targeted delivery technologies for blood-brain barrier, peripheral nerves, and dorsal root ganglia

• Novel approaches to protein knockdown or modulation (e.g. siRNA, gene therapy, protein degradation)

Out of Scope

• Opioid analgesics

• CNS injury indications (e.g. spinal cord injury pain)

• Hospital-based acute pain treatments (e.g. peri-operative pain treatment)

• Repurposing

Lilly has a growing portfolio of solutions for patients in dermatology, rheumatology, and gastroenterology.

Focus Indications

Dermatology

• Atopic dermatitis

• Psoriasis

• Hidradenitis suppurativa

• Pemphigus vulgaris

Rheumatology

• Rheumatoid arthritis

• Psoriatic arthritis

• Spondyloarthropathy (PsA, axSpA)

• Systemic lupus erythematosus

Gastroenterology

• Crohn’s disease

• Ulcerative colitis

• Eosinophilic esophagitis

• Celiac Disease

Others

• Fibrosis - primarily IPF and scleroderma

• Progressive forms of Multiple sclerosis (MS)

• Other diseases of high unmet need in dermatology, rheumatology, and gastroenterology

Fields of Interest

• Adaptive Immunity – T-cell biology, B-cell biology, cytokine signaling

• Innate Immunity – Myeloid cells, neutrophils, dendritic cells, fibrosis mechanisms

• Immune Resolution – Checkpoint receptors, Treg biology, immunometabolism, tolerance

Technologies

• Nanoparticles for use in tolerance

• Tissue-targeted oral delivery platforms

• Cellular therapies

• Microbiome – limited to microbe-derived molecules that can be chemically optimized

Out of Scope

• Infectious disease indications

• Antibiotics

• Vaccines

• Live bacterial therapies

• Bispecifics without new biology

• Topicals without proof of concept

Expanding the Druggable Space

• Genetic medicine platforms including RNA therapeutics, gene editing, and gene therapy

• In silico platforms for small molecule drug discovery

• Targeted protein degradation

• Antibody drug conjugates

Drug Targeting and Delivery

• Oral peptide delivery

• Nanoparticles for delivering nucleic-acid based therapies

• Conjugation and encapsulation approaches allowing targeting to specific tissues (e.g. CNS, pancreas, kidney)

• Delivery devices that can improve patient experience (e.g. connected solutions, ease of use)

• Delivery platforms that can enable new routes of administration (intrethecal delivery, large volume bolus infusers, etc.)

• Tissue targeted delivery of therapeutics

Digital Platforms and Therapeutics

• Biomarkers

• Patient stratification approaches

• Digital therapeutics

• Patient-facing apps

• Connected devices